Micronics Receives $2.6M Molecular Diagnostic Blood Screening Award Under Defense Medical Research and Development Program (DMRDP)
REDMOND, Wash., USA (October 18, 2010) – BusinessWire – Micronics, Inc., a development-stage company, today announced that the Department of Defense has awarded the company an Applied Research and Technology Development Award under the U.S. Army Medical Research and Materiel Command’s Polytrauma and Blast Injury project for advancement of its PanNAT system for point-of-care molecular diagnosis of infectious pathogens.
In the U.S. Army Medical Research and Material Command's Broad Area Announcement, the Armed Forces expressed interest in innovative medical technology to develop a highly accurate, rapid assay device for detecting bloodborne pathogens. The device needed would have a higher degree of sensitivity than existing equipment, and provide instant results, while being durable and fully functional in field testing to withstand wartime conditions.
In response, the PanNAT technology represents a significant advance over current nucleic acid-based assay systems, which are complex, expensive and can take several hours or days. Micronics’ PanNAT system is a sample-to-answer device that is easy to use; the lightweight, portable instrument processes a cartridge into which all reagents are incorporated for rapid disease detection. The award will advance the development of assays on the compact, WiFi-enabled, mains and / or battery-powered PanNAT instrument for the direct detection of multiple bloodborne pathogens in fresh blood samples. The specific pathogens to be detected are those for hepatitis B and C (HBV, HCV) as well as the human immunodeficiency virus (HIV). The assay is intended for use in the battlefield to screen out any infectious blood donated for transfusion.
Micronics has already begun work on the three-year project that began on September 30, 2010. The award funds a collaborative effort lead by Micronics’ chief scientific officer, John Gerdes, PhD, together with Wei Mei Ching, PhD/Senior Scientist, of the Naval Medical Research Command in Silver Spring, Maryland, and John D. Scott, MD/Professor, of the Hepatitis and Liver Clinic at the University of Washington in Seattle, Washington.
Micronics has developed an important patent estate in microfluidics – the ability to substantially reduce the reagents and sample volumes required to process a diagnostic test – together with related technologies that enable the direct processing of biological and environmental samples and the performance of highly accurate tests in a fraction of the time required by most molecular diagnostic tests in use today. Micronics is also a leading developer of custom product development for clients worldwide. For more information, please visit www.micronics.net or contact Karen Hedine, Micronics, Inc. Tel: 425-895-9197, ext. 126.
The goal of the Defense Medical Research and Development Program (DMRDP) is to advance the state of medical science in those areas of most pressing need and relevance to today’s battlefield experience. The objectives of the DMRDP are to discover and explore innovative approaches to protect, support and advance the health and welfare of military personnel, families and communities; to accelerate the transition of medical technologies into deployed products and to accelerate the translation of advances in knowledge into new standards of care for injury prevention, treatment of casualties, rehabilitation and training systems that can be applied in theater or in the clinical facilities of the Military Health System.
The views, opinions and findings contained in this release are those of Micronics, Inc. and do not necessarily reflect the views of the Department of Defense and should not be construed as an official DOD/Army policy.